Adcock Ingram Holdings Ltd
JSE:AIP
ROE
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
Peer Comparison
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| ZA |
A
|
Adcock Ingram Holdings Ltd
JSE:AIP
|
12.1B ZAR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
952.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
589.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
288.1B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
246B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
235.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
295.8B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.8B USD |
Loading...
|
Market Distribution
| Min | -1 980% |
| 30th Percentile | -27.8% |
| Median | -18.9% |
| 70th Percentile | 41.9% |
| Max | 480.3% |
Other Profitability Ratios
Adcock Ingram Holdings Ltd
Glance View
Nestled in the competitive landscape of the pharmaceutical industry, Adcock Ingram Holdings Ltd. stands as a testament to resilience and evolution. Originating in South Africa, the company has built a legacy that combines a strong local presence with strategic global aspirations. Adcock Ingram’s journey is marked by an adaptive approach that blends innovation with consumer health needs. Its primary revenue streams flow from the development, manufacturing, and distribution of a wide array of healthcare products, including prescription medicines, over-the-counter formulations, and hospital medications. By maintaining a robust supply chain and nurturing partnerships both locally and internationally, the company ensures the steady availability of essential healthcare products across markets. The company’s recipe for success is enriched by a deep-rooted commitment to quality and research-driven practices. By investing in cutting-edge manufacturing facilities and a well-structured distribution network, Adcock Ingram manages to sustain efficiency and scale. This approach does not merely hinge on the core pharmaceutical business but extends to leveraging diverse consumer brands across various segments such as personal care and nutritional products. Their diverse portfolio not only mitigates risks associated with the volatile pharmaceutical industry but also aligns with the ever-evolving consumer health trends. In essence, Adcock Ingram thrives by intertwining strategic foresight with robust operational excellence, steadfastly serving the health and well-being of its customers.
See Also
ROE is calculated by dividing the Net Income by the Avg Total Equity.
The current ROE for Adcock Ingram Holdings Ltd is 15.3%, which is below its 3-year median of 15.4%.
Over the last 3 years, Adcock Ingram Holdings Ltd’s ROE has decreased from 16.1% to 15.3%. During this period, it reached a low of 13.8% on Dec 31, 2024 and a high of 16.9% on Jun 30, 2023.